Returns On Capital At C-MER Medical Holdings (HKG:3309) Paint A Concerning Picture
Returns On Capital At C-MER Medical Holdings (HKG:3309) Paint A Concerning Picture
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earned from that capital are also increasing. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. In light of that, when we looked at C-MER Medical Holdings (HKG:3309) and its ROCE trend, we weren't exactly thrilled.
如果你正在尋找一款多功能裝袋機,有幾件事需要注意。在一個完美的世界中,我們希望看到一家公司向其業務投入更多資本,理想情況下,從這些資本中獲得的回報也在增加。基本上,這意味着公司擁有可以繼續進行再投資的盈利計劃,這是複合機器的特徵。有鑑於此,當我們研究C-MER Medical Holdings(HKG: 3309)及其投資回報率趨勢時,我們並不十分興奮。
What Is Return On Capital Employed (ROCE)?
什麼是資本使用回報率(ROCE)?
For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for C-MER Medical Holdings, this is the formula:
對於那些不知道的人來說,ROCE是衡量公司年度稅前利潤(其回報率)的指標,相對於該業務使用的資本。要計算C-MER Medical Holdings的這一指標,公式如下:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)
0.058 = HK$139m ÷ (HK$2.8b - HK$362m) (Based on the trailing twelve months to June 2024).
0.058 = 1.39億港元 ÷(28億港元至3.62億港元)(基於截至2024年6月的過去十二個月)。
So, C-MER Medical Holdings has an ROCE of 5.8%. In absolute terms, that's a low return and it also under-performs the Healthcare industry average of 9.0%.
因此,C-MER Medical Holdings的投資回報率爲5.8%。從絕對值來看,這是一個低迴報,其表現也低於醫療保健行業9.0%的平均水平。
In the above chart we have measured C-MER Medical Holdings' prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering C-MER Medical Holdings for free.
在上圖中,我們將C-MER Medical Holdings先前的投資回報率與之前的表現進行了比較,但可以說,未來更爲重要。如果你願意,你可以免費查看報道C-MER Medical Holdings的分析師的預測。
The Trend Of ROCE
ROCE 的趨勢
When we looked at the ROCE trend at C-MER Medical Holdings, we didn't gain much confidence. To be more specific, ROCE has fallen from 7.7% over the last five years. However it looks like C-MER Medical Holdings might be reinvesting for long term growth because while capital employed has increased, the company's sales haven't changed much in the last 12 months. It may take some time before the company starts to see any change in earnings from these investments.
當我們查看C-MER Medical Holdings的投資回報率趨勢時,我們並沒有獲得太大的信心。更具體地說,投資回報率從過去五年的7.7%有所下降。但是,看來C-MER Medical Holdings可能正在進行再投資以實現長期增長,因爲儘管動用資本有所增加,但該公司的銷售額在過去12個月中沒有太大變化。公司可能需要一段時間才能開始看到這些投資的收益發生任何變化。
The Bottom Line
底線
In summary, C-MER Medical Holdings is reinvesting funds back into the business for growth but unfortunately it looks like sales haven't increased much just yet. Since the stock has declined 59% over the last five years, investors may not be too optimistic on this trend improving either. In any case, the stock doesn't have these traits of a multi-bagger discussed above, so if that's what you're looking for, we think you'd have more luck elsewhere.
總而言之,C-MER Medical Holdings正在將資金再投資到該業務中以實現增長,但不幸的是,銷售額似乎還沒有太大增長。由於該股在過去五年中下跌了59%,因此投資者對這一趨勢的改善可能也不太樂觀。無論如何,該股票不具有上面討論的多袋裝股票的特徵,因此,如果您正在尋找這種特徵,我們認爲您在其他地方會更幸運。
If you're still interested in C-MER Medical Holdings it's worth checking out our FREE intrinsic value approximation for 3309 to see if it's trading at an attractive price in other respects.
如果你仍然對C-MER Medical Holdings感興趣,值得查看我們的免費3309內在價值近似值,看看它在其他方面的交易價格是否具有吸引力。
While C-MER Medical Holdings isn't earning the highest return, check out this free list of companies that are earning high returns on equity with solid balance sheets.
儘管C-MER Medical Holdings的回報率並不高,但請查看這份免費的股票回報率高、資產負債表穩健的公司名單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。